Preferential induction of IL-10 in APC correlates with a switch from Th1 to Th2 response following infection with a low pathogenic variant of Theiler's virus.
Theiler's murine encephalomyelitis virus induces immune-mediated demyelination in susceptible mice after intracerebral inoculation. A naturally occurring, low pathogenic Theiler's murine encephalomyelitis virus variant showed a single amino acid change within a predominant Th epitope from lysine to arginine at position 244 of VP1. This substitution is the only one present in the entire viral capsid proteins. In this paper, we demonstrate that the majority of T cells specific for VP1(233-250) and VP2(74-86) from wild-type virus-infected mice are Th1 type and these VP1-specific cells poorly recognize the variant VP1 epitope (VP1(K244R)) containing the substituted arginine. In contrast, the Th2-type T cell population specific for these epitopes predominates in variant virus-infected mice. Immunization with UV-inactivated virus or VP1 epitope peptides could not duplicate the preferential Th1/Th2 responses following viral infection. Interestingly, the major APC populations, such as dendritic cells and macrophages, produce IL-12 on exposure to the pathogenic wild-type virus, whereas they preferentially produce IL-10 in response to the low pathogenic variant virus. Thus, such a spontaneous mutant virus may have a profoundly different capability to induce Th-type responses via selective production of cytokines involved in T cell differentiation and the consequent pathogenicity of virally induced immune-mediated inflammatory diseases.
Palma
JoAnn P
JP
Department of Microbiology-Immunology and Pathology, Northwestern University Medical School, Chicago, IL 60611, USA.
Yauch
Robert L
RL
Kang
Hee-Kap
HK
Lee
Hee-Gu
HG
Kim
Byung S
BS
D000595:Amino Acid Sequence; D000818:Animals; D000938:Antigen-Presenting Cells / Q000276:immunology* / Q000378:metabolism* / Q000821:virology; D000956:Antigens, Viral / Q000008:administration & dosage / Q000276:immunology; D002213:Capsid / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D036022:Capsid Proteins; D018188:Cardiovirus Infections / Q000276:immunology* / Q000821:virology; D002460:Cell Line; D002999:Clone Cells; D016207:Cytokines / Q000096:biosynthesis; D018984:Epitopes, T-Lymphocyte / Q000008:administration & dosage / Q000096:biosynthesis; D005260:Female; D007276:Injections, Intraventricular; D016753:Interleukin-10 / Q000096:biosynthesis*; D007376:Interleukin-2 / Q000096:biosynthesis; D008213:Lymphocyte Activation / Q000235:genetics; D051379:Mice; D008815:Mice, Inbred Strains; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000008:administration & dosage / Q000276:immunology; D018417:Th1 Cells / Q000276:immunology* / Q000378:metabolism; D018418:Th2 Cells / Q000276:immunology* / Q000378:metabolism; D017945:Theilovirus / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity*
D000956:Antigens, Viral; D036022:Capsid Proteins; D016207:Cytokines; D018984:Epitopes, T-Lymphocyte; D007376:Interleukin-2; D010446:Peptide Fragments; C442551:VP1 protein, Theilovirus; D016753:Interleukin-10